Symposia: Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders
Program: Oral and Poster Abstracts
Type: Poster
Hematology Disease Topics & Pathways:
Research, Antibody Therapy, Viral, Lymphoid Leukemias, Acute Myeloid Malignancies, ALL, Hodgkin lymphoma, Combination therapy, AML, Adult, Clinical Practice (Health Services and Quality), Lymphomas, CLL, Non-Hodgkin lymphoma, APL, Translational Research, Epidemiology, Elderly, Workforce, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Chemotherapy, Plasma Cell Disorders, B Cell lymphoma, CML, Clinical Research, Health outcomes research, Diversity, Equity, and Inclusion (DEI), T Cell lymphoma, Chronic Myeloid Malignancies, Health disparities research, Pediatric, Education, Supportive Care, Diseases, Indolent lymphoma, Therapy sequence, Patient-reported outcomes, Treatment Considerations, Infectious Diseases, Biological therapies, Aggressive lymphoma, Real-world evidence, Adverse Events, Lymphoid Malignancies, Non-Biological therapies, Registries, Young adult , Myeloid Malignancies, Emerging technologies, Monoclonal Antibody Therapy, Survivorship, Technology and Procedures, Study Population, Human, Measurable Residual Disease
Type: Poster
Hematology Disease Topics & Pathways:
Research, Antibody Therapy, Viral, Lymphoid Leukemias, Acute Myeloid Malignancies, ALL, Hodgkin lymphoma, Combination therapy, AML, Adult, Clinical Practice (Health Services and Quality), Lymphomas, CLL, Non-Hodgkin lymphoma, APL, Translational Research, Epidemiology, Elderly, Workforce, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Chemotherapy, Plasma Cell Disorders, B Cell lymphoma, CML, Clinical Research, Health outcomes research, Diversity, Equity, and Inclusion (DEI), T Cell lymphoma, Chronic Myeloid Malignancies, Health disparities research, Pediatric, Education, Supportive Care, Diseases, Indolent lymphoma, Therapy sequence, Patient-reported outcomes, Treatment Considerations, Infectious Diseases, Biological therapies, Aggressive lymphoma, Real-world evidence, Adverse Events, Lymphoid Malignancies, Non-Biological therapies, Registries, Young adult , Myeloid Malignancies, Emerging technologies, Monoclonal Antibody Therapy, Survivorship, Technology and Procedures, Study Population, Human, Measurable Residual Disease
Sunday, December 8, 2024: 6:00 PM-8:00 PM
Halls G-H
(San Diego Convention Center)
See more of: Oral and Poster Abstracts
*signifies non-member of ASH